NewsRx

Search our medical news database

Melanoma

Interferon Therapy Does Not Inhibit GMK Vaccine Effectiveness

Published in Cancer Weekly, May 8th, 2001

by N.R. Saltmarsh, staff medical writer - Giving high-dose interferon therapy with the GM2-KLH/QS-21 (GMK) vaccine does not inhibit immune response and appears to prolong relapse-free survival in high-risk melanoma patients.

High-dose interferon alfa 2b (IFN alpha 2b) is the only established adjuvant therapy of resectable high-risk melanoma, while GMK is one of the best vaccine candidates for the disease.

J.M. Kirkwood and colleagues at the University of Pittsburgh Medical Center, Pennsylvania, proposed that both given together might be more effective than either alone.

Their Phase II study evaluated the combination of GMK and...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook